Ponatinib
Sign in to save this workspacePrimary targets: BCR_ABL, ABL1, ABL2_ARG · FDA status: FDA Approved
Selectivity scorecard
KISS
78.23
Gini
0.534
CATDS
0.007
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Ponatinib. Strongest target: ABL1 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ABL1 | 100.0% | 0.0% |
| 2 | ABL2_ARG | 100.0% | 0.0% |
| 3 | BLK | 100.0% | 0.0% |
| 4 | C_KIT | 100.0% | 0.0% |
| 5 | DDR2 | 100.0% | 0.0% |
| 6 | EPHA6 | 100.0% | 0.0% |
| 7 | FLT1_VEGFR1 | 100.0% | 0.0% |
| 8 | LYN | 100.0% | 0.0% |
| 9 | LYN_B | 100.0% | 0.0% |
| 10 | NEK4 | 100.0% | 0.0% |
| 11 | PDGFRB | 100.0% | 0.0% |
| 12 | RAF1 | 100.0% | 0.0% |
| 13 | RET | 100.0% | 0.0% |
| 14 | SRMS | 100.0% | 0.0% |
| 15 | PDGFRA | 100.0% | 0.0% |
| 16 | EPHB2 | 100.0% | 0.0% |
| 17 | C_SRC | 99.8% | 0.2% |
| 18 | HCK | 99.8% | 0.2% |
| 19 | FLT4_VEGFR3 | 99.8% | 0.2% |
| 20 | HPK1_MAP4K1 | 99.7% | 0.3% |
Selectivity landscape
Where Ponatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Ponatinib.
Atlas insights for Ponatinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 3883.13 | |
| ALLOGRAFT_REJECTION | 12429.44 | |
| ANDROGEN_RESPONSE | 2571.43 | |
| ANGIOGENESIS | 2368.01 | |
| APICAL_JUNCTION | 13694.09 | |
| APICAL_SURFACE | 1517.61 | |
| APOPTOSIS | 9910.45 | |
| BILE_ACID_METABOLISM | 1454.64 | |
| CHOLESTEROL_HOMEOSTASIS | 2076.55 | |
| COAGULATION | 1711.16 | |
| COMPLEMENT | 7767.15 | |
| DNA_REPAIR | 2532.55 | |
| E2F_TARGETS | 6512.35 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 2482.40 | |
| ESTROGEN_RESPONSE_EARLY | 4583.59 | |
| ESTROGEN_RESPONSE_LATE | 4084.42 | |
| FATTY_ACID_METABOLISM | 1212.01 | |
| G2M_CHECKPOINT | 6749.84 | |
| GLYCOLYSIS | 3622.54 | |
| HEDGEHOG_SIGNALING | 1699.56 | |
| HEME_METABOLISM | 2933.25 | |
| HYPOXIA | 6167.43 | |
| IL2_STAT5_SIGNALING | 4864.13 | |
| IL6_JAK_STAT3_SIGNALING | 8402.27 | |
| INFLAMMATORY_RESPONSE | 7616.16 | |
| INTERFERON_ALPHA_RESPONSE | 1525.81 | |
| INTERFERON_GAMMA_RESPONSE | 9703.83 | |
| KRAS_SIGNALING_DN | 1519.53 | |
| KRAS_SIGNALING_UP | 5073.67 | |
| MITOTIC_SPINDLE | 8608.72 | |
| MTORC1_SIGNALING | 5588.01 | |
| MYC_TARGETS_V1 | 4680.88 | |
| MYC_TARGETS_V2 | 1041.55 | |
| MYOGENESIS | 4296.88 | |
| NOTCH_SIGNALING | 353.13 | |
| OXIDATIVE_PHOSPHORYLATION | 2178.32 | |
| P53_PATHWAY | 5193.84 | |
| PANCREAS_BETA_CELLS | 456.33 | |
| PEROXISOME | 1259.09 | |
| PI3K_AKT_MTOR_SIGNALING | 14060.45 | |
| PROTEIN_SECRETION | 3132.30 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 665.65 | |
| SPERMATOGENESIS | 2308.89 | |
| TGF_BETA_SIGNALING | 2840.37 | |
| TNFA_SIGNALING_VIA_NFKB | 6512.54 | |
| UNFOLDED_PROTEIN_RESPONSE | 1813.98 | |
| UV_RESPONSE_DN | 7354.88 | |
| UV_RESPONSE_UP | 4994.14 | |
| WNT_BETA_CATENIN_SIGNALING | 2941.25 | |
| XENOBIOTIC_METABOLISM | 2568.49 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.840 |
| SRR23303752 | — | 0.835 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.824 |
| aMVAC.P_005_TURBT_S223 | — | 0.823 |
| SRR10899984 | — | 0.822 |
Annotations
Sign in to read and post annotations.
Loading…